Cell-permeable dual inhibitors of protein kinases CK2 and PIM-1: structural features and pharmacological potential

[1]  C. Girardi,et al.  Exploiting the repertoire of CK2 inhibitors to target DYRK and PIM kinases. , 2013, Biochimica et biophysica acta.

[2]  R. Moo-Puc,et al.  Synthesis and Antimicrobial Activities of New Polyhalogenated Benzimidazoles. , 2013 .

[3]  Dario R Alessi,et al.  Kinase drug discovery--what's next in the field? , 2013, ACS chemical biology.

[4]  Y. Miyata,et al.  Effects of the CK2 Inhibitors CX-4945 and CX-5011 on Drug-Resistant Cells , 2012, PloS one.

[5]  R. Moo-Puc,et al.  Synthesis and Antimicrobial Activities of New Polyhalogenated Benzimidazoles , 2012 .

[6]  Marc R. Knecht,et al.  Casein Kinase 2α Regulates Multidrug Resistance-Associated Protein 1 Function via Phosphorylation of Thr249 , 2012, Molecular Pharmacology.

[7]  Adam Siddiqui-Jain,et al.  Novel potent dual inhibitors of CK2 and Pim kinases with antiproliferative activity against cancer cells. , 2012, Bioorganic & medicinal chemistry letters.

[8]  M. Roizen,et al.  Hallmarks of Cancer: The Next Generation , 2012 .

[9]  L. Pinna,et al.  Structural features underlying the selectivity of the kinase inhibitors NBC and dNBC: role of a nitro group that discriminates between CK2 and DYRK1A , 2012, Cellular and Molecular Life Sciences.

[10]  Roberto Battistutta,et al.  Unprecedented selectivity and structural determinants of a new class of protein kinase CK2 inhibitors in clinical trials for the treatment of cancer. , 2011, Biochemistry.

[11]  J. Jongstra,et al.  The oncogenic PIM kinase family regulates drug resistance through multiple mechanisms. , 2011, Drug resistance updates : reviews and commentaries in antimicrobial and anticancer chemotherapy.

[12]  J. Bain,et al.  ATP site-directed inhibitors of protein kinase CK2: an update. , 2011, Current topics in medicinal chemistry.

[13]  Randy J. Read,et al.  Overview of the CCP4 suite and current developments , 2011, Acta crystallographica. Section D, Biological crystallography.

[14]  D. Hanahan,et al.  Hallmarks of Cancer: The Next Generation , 2011, Cell.

[15]  M. Nawijn,et al.  For better or for worse: the role of Pim oncogenes in tumorigenesis , 2011, Nature Reviews Cancer.

[16]  Adam Siddiqui-Jain,et al.  CX-4945, an orally bioavailable selective inhibitor of protein kinase CK2, inhibits prosurvival and angiogenic signaling and exhibits antitumor efficacy. , 2010, Cancer research.

[17]  S. Knapp,et al.  New potent dual inhibitors of CK2 and Pim kinases: discovery and structural insights , 2010, FASEB journal : official publication of the Federation of American Societies for Experimental Biology.

[18]  Stefan Knapp,et al.  PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers , 2010, Haematologica.

[19]  C. Van Waes,et al.  Emergence of protein kinase CK2 as a key target in cancer therapy , 2010, BioFactors.

[20]  P. Emsley,et al.  Features and development of Coot , 2010, Acta crystallographica. Section D, Biological crystallography.

[21]  R. Morphy.  Selectively nonselective kinase inhibition: striking the right balance. , 2010, Journal of medicinal chemistry.

[22]  Randy J. Read,et al.  Acta Crystallographica Section D Biological , 2003 .

[23]  L. Pinna,et al.  Assessment of CK2 constitutive activity in cancer cells. , 2010, Methods in enzymology.

[24]  Rongshi Li,et al.  Kinase Inhibitor Drugs , 2009 .

[25]  S. Moro,et al.  Quinalizarin as a potent, selective and cell-permeable inhibitor of protein kinase CK2. , 2009, The Biochemical journal.

[26]  D. Litchfield,et al.  Protein Kinase CK2 in Health and Disease , 2009, Cellular and Molecular Life Sciences.

[27]  A. Kraft,et al.  Synthesis and evaluation of novel inhibitors of Pim-1 and Pim-2 protein kinases. , 2009, Journal of medicinal chemistry.

[28]  J. Bain,et al.  The selectivity of inhibitors of protein kinase CK2: an update. , 2008, The Biochemical journal.

[29]  F. Seela,et al.  Substituted benzimidazoles: antiviral activity and synthesis of nucleosides , 2008 .

[30]  O. Issinger,et al.  The CK2 alpha/CK2 beta interface of human protein kinase CK2 harbors a binding pocket for small molecules. , 2008, Chemistry & biology.

[31]  P. Cohen,et al.  The selectivity of protein kinase inhibitors: a further update. , 2007, The Biochemical journal.

[32]  P. Graczyk.  Gini coefficient: a new way to express selectivity of kinase inhibitors against a family of kinases. , 2007, Journal of medicinal chemistry.

[33]  L. Pinna,et al.  Pharmacological inhibition of protein kinase CK2 reverts the multidrug resistance phenotype of a CEM cell line characterized by high CK2 level , 2007, Oncogene.

[34]  Randy J. Read,et al.  Phaser crystallographic software , 2007, Journal of applied crystallography.

[35]  L. Pinna,et al.  Protein kinase CK2 phosphorylates and upregulates Akt/PKB , 2005, Cell Death and Differentiation.

[36]  L. Pinna,et al.  2-Dimethylamino-4,5,6,7-tetrabromo-1H-benzimidazole: a novel powerful and selective inhibitor of protein kinase CK2. , 2004, Biochemical and biophysical research communications.

[37]  L. Pinna,et al.  Protein kinase CK2 inhibitor 4,5,6,7-tetrabromobenzotriazole (TBB) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 (HS1) in Jurkat cells. , 2002, The Biochemical journal.

[38]  S. Davies,et al.  Selectivity of 4,5,6,7‐tetrabromobenzotriazole, an ATP site‐directed inhibitor of protein kinase CK2 (‘casein kinase‐2’) , 2001, FEBS letters.

[39]  J. Kotera,et al.  Protein kinase CK 2 : in search for its regulation , 2017 .

[40]  P Willett,et al.  Development and validation of a genetic algorithm for flexible docking. , 1997, Journal of molecular biology.

[41]  J. Glavy,et al.  Identification of the in Vivo Phosphorylation Sites for Acidic-directed Kinases in Murine mdr1b P-glycoprotein* , 1997, The Journal of Biological Chemistry.

[42]  D. Shugar,et al.  Halogenated benzimidazoles and benzotriazoles as selective inhibitors of protein kinases CK I and CK II from Saccharomyces cerevisiae and other sources. , 1995, Biochemical and biophysical research communications.

[43]  L. Pinna,et al.  Ribofuranosyl-benzimidazole derivatives as inhibitors of casein kinase-2 and casein kinase-1. , 1990, European journal of biochemistry.

[44]  R. Weinmann,et al.  Casein kinase type II is involved in the inhibition by 5,6-dichloro-1-beta-D-ribofuranosylbenzimidazole of specific RNA polymerase II transcription. , 1986, The Journal of biological chemistry.

[45]  R. Stolarski,et al.  Stereospecific Synthesis by the Sodium Salt Glycosylation Method of Halogeno Benzimidazole 2′ -Deoxyribose Analogues of the Inhibitor of hnRNA Synthesis, 5,6-Dichloro-1-(β-ᴅ-ribofuranosyl)benzimidazole (DRB) , 1985, Zeitschrift fur Naturforschung. Section C, Biosciences.

[46]  D. Penzo,et al.  Protein kinase CK 2 inhibitor 4 , 5 , 6 , 7-tetrabromobenzotriazole ( TBB ) induces apoptosis and caspase-dependent degradation of haematopoietic lineage cell-specific protein 1 ( HS 1 ) in Jurkat cells , 2022 .